US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

38.74

+0.68001.79%

Post-market: 38.740.00000.00%19:30 EDT

Volume:181.14K

Turnover:6.94M

Market Cap:261.50M

PE:- -

High:38.92

Open:38.35

Low:38.07

Close:38.06

52wk High:41.49

52wk Low:22.33

Shares:6.75M

Float Shares:6.75M

Volume Ratio:1.14

T/O Rate:2.68%

Dividend:0.28

Dividend Rate:0.73%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)

Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer

MT Newswires Live

Moderna CFO James M. Mock Disposes of 34,836 Common Shares Worth $4.68 Million

Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

THOMSON REUTERS

Biofrontera announces FDA approval of Ameluz supplemental new drug application

Scholar Rock Wins FDA Approval for SMA Therapy

Scholar Rock price target raised to $84 from $76 at BMO Capital

Immunocore achieves target patient enrollment in TEBE-AM clinical trial

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

Cellectis pivots to in vivo gene editing and exits key CAR-T programs

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Vertex Minerals Revises Timeline for Proposed Securities Issue

Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)

Scholar Rock announces FDA approval of isembyld

Moderna Inc. Stock Rallies 5.4%, Outperforms Peers

IntegraGen receives rival takeover bids amid court‑ordered restructuring

Pharming wins FDA nod to extend Joenja use to younger APDS children

Moderna Inc Stock (MRNA) Moved Up by 8.63% on Sep 11: A Full Analysis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/IDNA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":38.74,"timestamp":1789416000000,"preClose":38.06,"halted":0,"volume":181144,"hourTrading":{"tag":"盘后","latestPrice":38.74,"preClose":38.74,"latestTime":"19:30 EDT","volume":75,"amount":2918.7,"timestamp":1789428601745,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01786652653704676,"floatShares":6750000,"shares":6750000,"eps":0,"marketStatus":"Not Yet Opened","change":0.68,"latestTime":"09-14 16:00:00 EDT","open":38.35,"high":38.92,"low":38.07,"amount":6939585.339168,"amplitude":0.022333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":38.06,"sharesOutstanding":5100000,"nav":37.991633,"aum":258343104.4,"dividendRate":0.007269,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":38.02,"preClose":38.06,"latestTime":"09:20 EDT","volume":58,"amount":2206.31739,"timestamp":1789392005613,"change":-0.04,"changeRate":-0.001051,"amplitude":0.001689},"postHourTrading":{"tag":"盘后","latestPrice":38.74,"preClose":38.74,"latestTime":"19:30 EDT","volume":75,"amount":2918.7,"timestamp":1789428601745,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.136615,"impliedVol":0.1375,"impliedVolPercentile":0.284},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.136615,"shares":6750000,"dividePrice":0.2816,"high":38.92,"amplitude":0.022333,"preClose":38.06,"low":38.07,"week52Low":22.33,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":38.74,"eps":0,"divideRate":0.007269,"volume":181144,"delay":0,"ttmEps":0,"open":38.35,"prevYearClose":26.19,"prevWeekClose":38.06,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":39.77,"twentyDayClose":35.23,"sixtyDayClose":30.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667966776","title":"Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667966776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667966776?lang=en_us&edition=fundamental","pubTime":"2026-09-15 05:10","pubTimestamp":1789420212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and ArriVent BioPharma, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","IE00BJT1NW94.SGD","LU0109394709.USD","RVMD","LU0128526141.USD","HCSG","BK4139","IE0009354923.USD","PTH","IE00BJJMRZ35.SGD","BK4585","BK4588","IE0009355771.USD","IE00B4R5TH58.HKD","BK4581","IDNA","LU0320765992.SGD","XBI","LU0029874061.USD","IE00BFTCPJ56.SGD","CANC","LU0889565916.HKD","XLV","IE00B2B36J28.USD","IE0002141913.USD","BBH","BK4137","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695932","title":"Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695932","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695932?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:35","pubTimestamp":1789418122,"startTime":"0","endTime":"0","summary":"Revolution Medicines  said Monday that the US Food and Drug Administration has given breakthrough therapy designation to Rasonque plus chemotherapy to treat pancreatic cancer.The company said Rasonque was recently approved by the US FDA to treat adults with metastatic pancreatic cancer who have received at least one systemic therapy or who are not candidates for multiagent systemic therapy.Revolution said the use of Rasonque plus chemotherapy for treatment-naive metastatic pancreatic adenocarcinoma is still investigational, with safety and efficacy not yet established.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","IE0009354923.USD","BK4588","IE0009355771.USD","PTH","LABU","RVMD","IDNA","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BBH","IE00BJT1NW94.SGD","IE00B2B36J28.USD","CANC","LU0889565916.HKD","LU0109394709.USD","BK4585","BK4139","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695518","title":"Moderna CFO James M. Mock Disposes of 34,836 Common Shares Worth $4.68 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695518","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695518?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:25","pubTimestamp":1789417559,"startTime":"0","endTime":"0","summary":"Moderna CFO James M. Mock disposes of 34,836 common shares worth $4.68 millionModerna CFO Mock James M disclosed sales of 34,836 common shares on Sep. 10, 2026 at USD 134.49.He also exercised stock op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL8rXTDg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Moderna CFO James M. Mock Disposes of 34,836 Common Shares Worth $4.68 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGHT","MRNX","BK4139","BK4588","WDNA","MRNY","BK4548","BK4501","BK4568","BK4534","BK4551","GNOM","BK4532","IDNA","MRNA","BK4585","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667953426","title":"Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2667953426","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667953426?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:15","pubTimestamp":1789416936,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the FDA has granted Breakthrough Therapy Designation to Rasonque, the company’s RAS multi-selective inhi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-granted-breakthrough-therapy-designation-to-rasonque-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-granted-breakthrough-therapy-designation-to-rasonque-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU0109394709.USD","RVMD","BK4139","IE0009354923.USD","PTH","IE00BJJMRZ35.SGD","BK4588","BK4585","IE0009355771.USD","IE00B4R5TH58.HKD","IDNA","LU0320765992.SGD","IE00BFTCPJ56.SGD","CANC","LU0889565916.HKD","IE00B2B36J28.USD","IE0002141913.USD","BBH","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667769375","title":"Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667769375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667769375?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA3JTDPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","RVMD","BK4139","IE0009355771.USD","IE00B4R5TH58.HKD","IDNA","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0002141913.USD","LU0109394709.USD","IE0009354923.USD","CANC","PTH","IE00B2B36J28.USD","BBH","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661630","title":"Biofrontera announces FDA approval of Ameluz supplemental new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661630","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661630?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:35","pubTimestamp":1789392922,"startTime":"0","endTime":"0","summary":"Biofrontera (BFRI) announced that the FDA has approved the company’s supplemental new drug application, or sNDA, for Ameluz topical gel, 10%, in co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","IEIH","IYH","SYNB","TBXU","IDNA","FRTY","MEDI","PINK","GNMX","LABU","PSCH","RSPH","BK4007","LFSC","BK4588","IBB","BK4585","TECB","XLVX","MRNY","BFRI","GDOC","BMED","NVIB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066661","title":"Scholar Rock Wins FDA Approval for SMA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066661","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066661?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:32","pubTimestamp":1789389127,"startTime":"0","endTime":"0","summary":"The latest update is out from Scholar Rock Holding ( ($SRRK) ). On September 11, 2026, Scholar Rock announced U.S. FDA approval of ISEMBYLD (apiteg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","IYH","MRNY","TECB","PSCH","IDNA","MEDI","PINK","BMED","SYNB","FRTY","XLVX","LABU","NVIB","BK4585","BBP","GNMX","IEIH","MRNX","LFSC","GDOC","TBXU","RSPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134663","title":"Scholar Rock price target raised to $84 from $76 at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385772,"startTime":"0","endTime":"0","summary":"BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","SYNB","BK4139","MRNY","SRRK","IEIH","FRTY","BK4588","BK4585","MRNX","IBRN","LFSC","IBB","GDOC","BBP","BMED","PSCH","GNMX","TECB","XLVX","THNR","NVIB","RSPH","IDNA","IYH","LABU","PINK","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668170","title":"Immunocore achieves target patient enrollment in TEBE-AM clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668170?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:20","pubTimestamp":1789384814,"startTime":"0","endTime":"0","summary":"Immunocore (IMCR) announced the achievement of target patient enrollment in the TEBE-AM clinical trial. With target enrollment now achieved, patien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunocore-achieves-target-patient-enrollment-in-tebe-am-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunocore-achieves-target-patient-enrollment-in-tebe-am-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","BK4139","IMCR","BK4505","IDNA","NVIB","GDOC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667565199","title":"BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2667565199","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667565199?lang=en_us&edition=fundamental","pubTime":"2026-09-14 16:00","pubTimestamp":1789372800,"startTime":"0","endTime":"0","summary":"Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3360734/0/en/biontech-and-oncoc4-present-updated-data-showing-gotistobart-nearly-doubled-median-overall-survival-versus-standard-of-care-chemotherapy-in-previously-treated-squamous-non-small-ce.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","L","BK4124","LU0053666078.USD","BK4107","SMP","IDNA","LU0210528500.USD","LU2487616109.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667376655","title":"Cellectis pivots to in vivo gene editing and exits key CAR-T programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2667376655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667376655?lang=en_us&edition=fundamental","pubTime":"2026-09-14 15:15","pubTimestamp":1789370144,"startTime":"0","endTime":"0","summary":"Cellectis SA ( ($FR:ALCLS) ) has provided an announcement. Cellectis has approved a strategic shift to focus on in vivo gene editing, advancing two...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cellectis-pivots-to-in-vivo-gene-editing-and-exits-key-car-t-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cellectis-pivots-to-in-vivo-gene-editing-and-exits-key-car-t-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","WDNA","HELX","GNMX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653981","title":"Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653981","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653981?lang=en_us&edition=fundamental","pubTime":"2026-09-14 14:40","pubTimestamp":1789368000,"startTime":"0","endTime":"0","summary":"Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by con","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3360712/0/en/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","BK4156","BK4139","SYNB","HELX","CLLS","WDNA","GNMX","IDNA","NC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635488","title":"Vertex Minerals Revises Timeline for Proposed Securities Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635488?lang=en_us&edition=fundamental","pubTime":"2026-09-14 07:40","pubTimestamp":1789342824,"startTime":"0","endTime":"0","summary":"Vertex Minerals Ltd. ( ($AU:VTX) ) has provided an update. Vertex Minerals Ltd. has updated its proposed securities placement timetable, revising t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-revises-timeline-for-proposed-securities-issue?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-revises-timeline-for-proposed-securities-issue?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089984988.USD","LU1674673428.USD","BK4588","IBBQ","IE00BZ9MQY76.HKD","BK4533","BK4532","IE00B4R5TH58.HKD","IDNA","LU2468319806.SGD","IE00B2B36J28.USD","SG9999001176.USD","LU2362541273.HKD","SGXZ57979304.SGD","PBE","LU0079474960.USD","IBB","BK4109","LU0234570918.USD","LU0432979614.USD","LU1815336091.USD","SG9999001176.SGD","LU1674673691.USD","LU1559883803.SGD","TBXU","IE0009355771.USD","MTX","LU0417517546.SGD","GNMX","IE00B19Z9P08.USD","LU0061475181.USD","BIB","IE00B894F039.SGD","LU1430594728.SGD","LU1093756325.SGD","LU0889565916.HKD","LU0566484027.USD","LU0058720904.USD","LU0757428866.USD","LU2462157665.USD","IE00BJT1NW94.SGD","LU1585245621.USD","LU0320765992.SGD","VERX","BK4585","IE00BJJMRZ35.SGD","LU0256863811.USD","BBH","VRTX","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635862","title":"Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635862","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635862?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:54","pubTimestamp":1789340092,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has secured U.S. FDA approval for Pixclara, the first FET-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","XLVX","MRNY","PSCH","IYH","BMED","FRTY","BK4588","IDNA","IEIH","SYNB","GDOC","RSPH","TECB","LFSC","GNMX","BK4585","BK4139","NVIB","LABU","PINK","TLX","MEDI","FET","TBXU","BBP","MRNX","BK4179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668081","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668081?lang=en_us&edition=fundamental","pubTime":"2026-09-14 01:20","pubTimestamp":1789320035,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Cooper Co (COO) with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B4R5TH58.HKD","BK4137","IE0002141913.USD","LU2272731782.SGD","IE0009355771.USD","LU0320765992.SGD","LABU","IDNA","CANC","PTH","LU2272731600.USD","IE00BJT1NW94.SGD","LU1992135472.HKD","LU0128526141.USD","IE00BJJMRZ35.SGD","HCSG","COO","LU1992135399.USD","BK4581","XLV","XBI","GB00BDT5M118.USD","BBH","IE00B2B36J28.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4585","LU0029874061.USD","RVMD","BK4588","LU2211815571.USD","IE0009354923.USD","BK4139","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577803","title":"Scholar Rock announces FDA approval of isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577803?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:30","pubTimestamp":1789165818,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","THNR","RSPH","IBB","MRNX","PSCH","IBRN","NVIB","SRRK","IYH","BK4588","SYNB","PINK","LABU","BMED","TECB","BK4585","FRTY","LFSC","MRNY","TBXU","XLVX","MEDI","GDOC","GNMX","IEIH","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666574302","title":"Moderna Inc. Stock Rallies 5.4%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666574302","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666574302?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:33","pubTimestamp":1789158780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. advanced 5.4% to $143.97 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.0% to 26,333.04 and the Dow Jones Industrial Average rising 1.0% to 52,573.29.This was the stock's second consecutive day of gains.Moderna Inc. closed 18.5% short of its 52-week high of $176.66, which the company achieved on August 19th.The stock outperformed some of its peers, as Johnson & Johnson fell 0.3% to $265.58, Pfizer Inc. rose 0.3% to $27.72, and Gilead Sciences Inc. fell 0.75% to $143.72.Trading volume totaled 15.3 million, compared to the 50-day average of 17.4 million.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357627491.SGD","IBBQ","LU0889565916.HKD","SG9999015978.USD","LU0965509283.SGD","MRNA","GNOM","TBXU","GILD","LU0965509101.SGD","LU1066051498.USD","LU1674673691.USD","BMED","LU0861579265.USD","LU1934455277.USD","LU0965509010.AUD","LU1778281490.HKD","BK4548","MRNY","BK4568","LU1430594728.SGD","BK4139","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU0114720955.EUR","LU0965508806.USD","BK4534","LU1585245621.USD","IE00B19Z3581.USD","LGHT","BBH","IDNA","IBB","LU0058720904.USD","LU1674673428.USD","SG9999015952.SGD","LU0109394709.USD","MEDI","BK4578","LU2468319806.SGD","IE00B3T34201.USD","TMED","SG9999015986.USD","LU1571399168.USD","LU1057294990.SGD","MRNX","BK4588","LU0289739699.SGD","WDNA","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666579410","title":"IntegraGen receives rival takeover bids amid court‑ordered restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2666579410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666579410?lang=en_us&edition=fundamental","pubTime":"2026-09-12 03:02","pubTimestamp":1789153348,"startTime":"0","endTime":"0","summary":"IntegraGen SA ( ($FR:ALINT) ) has provided an update. IntegraGen SA, a French genomics company focused on cancer and rare genetic diseases, provide...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/integragen-receives-rival-takeover-bids-amid-courtordered-restructuring?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/integragen-receives-rival-takeover-bids-amid-courtordered-restructuring?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","TARK","FWD","PBE","GNMX","DARP","GNOM","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666795715","title":"Pharming wins FDA nod to extend Joenja use to younger APDS children","url":"https://stock-news.laohu8.com/highlight/detail?id=2666795715","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666795715?lang=en_us&edition=fundamental","pubTime":"2026-09-12 02:32","pubTimestamp":1789151567,"startTime":"0","endTime":"0","summary":"Pharming Group ( ($NL:PHARM) ) has provided an announcement. Pharming has secured U.S. FDA approval for new 40 mg and 50 mg twice-daily doses of Jo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","BBP","IYH","TBXU","GNMX","IEIH","LFSC","IBB","SYNB","LABU","MRNX","NVIB","MRNY","BK4585","PINK","PSCH","FRTY","BMED","TECB","BK4588","RSPH","GDOC","IDNA","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666575576","title":"Moderna Inc Stock (MRNA) Moved Up by 8.63% on Sep 11: A Full Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2666575576","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666575576?lang=en_us&edition=fundamental","pubTime":"2026-09-12 01:15","pubTimestamp":1789146928,"startTime":"0","endTime":"0","summary":"• Moderna experienced upward volatility driven by renewed institutional buying and consolidation.\n• Phase 3 trial results for intismeran autogene validated its oncology platform.\n• Latest annual revenue is $1.94B with a net loss of $-2.82B.","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262164027-market-movers-mrna-20260911","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","MRNA","BK4551","BK4585","BK4534","GNOM","BK4532","BK4533","MRNY","IDNA","MRNX","BK4568","BK4548","BK4139","BK4588","WDNA","LGHT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}